Effect of Bismuth Add-on to Dual Therapy for Helicobacter Pylori Eradication

This study aims to compare the efficacy and safety of a bismuth-supplemented 14-day vonoprazan-based dual therapy ( triple therapy) versus a 14-day vonoprazan-based dual therapy without bismuth for first-line H. pylori eradication. Furthermore, the investigators will investigate the impact of these eradication regimens on the gut microbiota, the development of antibiotic resistance, and changes in metabolic syndrome indicators pre- and post-treatment.

NCT Number	NCT07576959
Lead Sponsor	National Taiwan University Hospital
Conditions	HELICOBACTER PYLORI INFECTIONS
Enrollment	990 participants
Start Date	2026-04-08
Primary Completion	2030-12-31 (estimated)
Study Completion	2032-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-08